Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy-Reference-Cited by-同舟云学术

Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy

Published:2021-06-30 Issue:6 Volume:4 Page:e2114904
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Dar Huma¹,Johansson Annelie¹,Nordenskjöld Anna²³,Iftimi Adina⁴,Yau Christina⁵,Perez-Tenorio Gizeh⁶⁷,Benz Christopher⁸,Nordenskjöld Bo⁶⁷,Stål Olle⁶⁷,Esserman Laura J.⁵,Fornander Tommy¹,Lindström Linda S.¹

Affiliation:

1. Department of Oncology and Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden

2. Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg, Sweden

3. Department of Medicine, Southern Älvsborg Hospital, Borås, Sweden

4. Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden

5. Department of Surgery, University of California, San Francisco, San Francisco

6. Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

7. Department of Oncology, Linköping University, Linköping, Sweden

8. Department of Medicine, University of California, San Francisco, San Francisco

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2781511/dar_2021_oi_210451_1624389755.9741.pdf

Reference30 articles.

1. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers.;Pichon;Br J Cancer,1996

2. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.;Davies;Lancet,2011

3. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group trials I to V.;Colleoni;J Clin Oncol,2016

4. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years.;Pan;N Engl J Med,2017

5. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases.;Carter;Cancer,1989

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer;npj Breast Cancer;2024-09-06

2. Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1);ESMO Open;2024-06

3. Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change;International Journal of Cancer;2024-03-30

4. Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy;International Journal of Molecular Sciences;2024-03-28

5. Lomitapide as a Potential Estrogen Receptor Inhibitor: A Computational Drug Repurposing Study;Kocaeli Üniversitesi Sağlık Bilimleri Dergisi;2024-03-15